cancers

MDPI

Correction

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. *Cancers* 2021, *13*, 3830

Ken Kudura [1,*], Florentia Dimitriou [2], Lucas Basler [3], Robert Förster [4], Daniela Mihic-Probst [5], Tim Kutzker [6], Reinhard Dummer [2], Joanna Mangana [2], Irene A. Burger [1,7] and Michael C. Kreissl [8]

1 Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland; irene.burger@usz.ch
2 Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland; florentia.dimitriou@usz.ch (F.D.); reinhard.dummer@usz.ch (R.D.); johanna.mangana@usz.ch (J.M.)
3 Center for Proton Therapy, Paul Scherrer Institute, 5232 Villigen, Switzerland; lucas.basler@psi.ch
4 Institute of Radiation Oncology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland; robert.foerster@ksw.ch
5 Institute of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland; daniela.mihic@usz.ch
6 Faculty of Applied Statistics, Humboldt University Berlin, 10117 Berlin, Germany; tim.kutzker@hu-berlin.de
7 Department of Nuclear Medicine, Cantonal Hospital Baden, 5404 Baden, Switzerland
8 Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University Hospital Magdeburg, 39120 Magdeburg, Germany; michael.kreissl@med.ovgu.de
* Correspondence: kenkudura@yahoo.de

Citation: Kudura, K.; Dimitriou, F.; Basler, L.; Förster, R.; Mihic-Probst, D.; Kutzker, T.; Dummer, R.; Mangana, J.; Burger, I.A.; Kreissl, M.C. Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. *Cancers* 2021, *13*, 3830. *Cancers* **2022**, *14*, 3268. https://doi.org/10.3390/cancers14133268

Received: 30 June 2021
Accepted: 26 July 2021
Published: 4 July 2022

The authors wish to make the following corrections to this paper [1]:

1. Add a citation in the Introduction section

In the original publication, the publication from Lucas Basler et al. [2] was not cited. The citation has now been inserted in the Introduction as reference [9]:

In order to predict the response to immunotherapy several outcome predictive biomarkers based on the histopathology of the primary tumor (i.e., tumor thickness, ulceration, mitotic rate) [8], standard blood samples (i.e., lactate dehydrogenase LDH, calcium-binding protein B S100B) [9] or clinical aspects (i.e., sentinel lymph node involvement, anatomical site of primary tumor, gender or age) [10] have been already discussed in the literature."

2. Ethical approval information needs to be updated:

The official and correct reference of the stated ethical approval is KEK-ZH-Nr: 2014-0193.

The correct statement is as below:

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Cantonal Ethics Committee of the Canton Zurich in Switzerland (protocol code KEK-ZH-Nr: 2014-0193) on 15 March 2017.

2.1. Patient Cohort

(...). All included patients consented the use of their clinical data for research purposes. This study was approved by the local ethics committee (protocol code KEK-ZH-Nr: 2014-0193) and conducted in compliance with Good Clinical Practice GCP-rules and the Declaration of Helsinki.

3. Missing Funding

In the original publication, the funder **Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13)** was not included.

The correct statement is as:

Funding: This research was funded by the Iten-Kohaut-Foundation (IA USZF27071) and the Cancer Research Center, Comprehensive Center Zurich, University Hospital Zurich (CRC_13).

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.

References

1. Kudura, K.; Dimitriou, F.; Basler, L.; Förster, R.; Mihic-Probst, D.; Kutzker, T.; Dummer, R.; Mangana, J.; Burger, I.A.; Kreissl, M.C. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. *Cancers* **2021**, *13*, 3830. [CrossRef]
2. Basler, L.; Gabryś, H.S.; Hogan, S.A.; Pavic, M.; Bogowicz, M.; Vuong, D.; Tanadini-Lang, S.; Förster, R.; Kudura, K.; Huellner, M.W.; et al. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma treated with Immune Checkpoint Inhibition. *Clin. Cancer Res.* **2020**, *26*, 4414–4425. [CrossRef] [PubMed]